32 results about "Topical agents" patented technology

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

To provide a PARP1 inhibitor and its use.SOLUTION: PARP1 inhibitors and pharmaceutical compositions comprising such inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. The compounds described herein are administered to a subject in need thereof according to standard pharmaceutical practice, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition. In one embodiment, the compounds of the invention can be administered to an animal. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.SELECTED DRAWING: None

A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.

Dermatological treatments and systems employing cooling, topicals, and / or abrasion are disclosed herein. The system can include a cold plate and a suspension assembly tip. The suspension assembly tip can be selectively coupleable to the cold plate. The suspension assembly tip can include a suspension tip and a suspension. The suspension tip can include a contact surface that can be contacted onto a patient's skin to provide a treatment. The suspension can couple to both the cold plate and to the suspension tip. The suspension can be thermally conductive so as to closely thermally couple the suspension tip to the cold plate, or the suspension tip can have a low thermal conductivity so as to not closely thermally coupled the suspension tip to the cold plate.

To develop a novel method for treatment of diseases leading to serious corneal and conjunctival epithelial damage resulting from functional impairment of corneal and conjunctival epithelial stem cells, including severe ocular surface disease attributable to chronic graft-versus-host disease.SOLUTION: The present invention provides a prophylactic or treatment agent for severe ocular surface disease for topical administration, comprising apocynin as an active ingredient.SELECTED DRAWING: None

and salts thereof, and contains, as a solvent, any of the solvents indicated by solvents (a)-(g). Solvent (a): dibasic acid diester; solvent (b): lower alcohol and dibasic acid diester; solvent (c): lower alcohol and dimethyl sulfoxide; solvent (d): dimethyl sulfoxide and dibasic acid diester; solvent (e): lower alcohol, dimethyl sulfoxide, and dibasic acid diester; solvent (f): lower alcohol and glycol; and solvent (g): lower alcohol, glycol, and dibasic acid diester.

The invention discloses an emulsion type suppository practical for vaginal administration, and relates to the technical field of pharmaceutical preparations, the suppository is a solid at room temperature, and can be converted into a cream type preparation in situ under vaginal temperature and wetting conditions; the suppository is composed of active and pharmaceutically acceptable auxiliary materials, the auxiliary materials comprise structural lipid, an emulsifier, a gel matrix and a pH regulator, and a suppository body is softened at body temperature and mixed with body fluid to form a cream mixture easy to coat on the mucous membrane surface in situ. The transformation process avoids greasy feeling and local discomfort possibly brought by a traditional greasy suppository, and also eliminates the trouble that the prefabricated cream needs to be matched with a special administration device, so that the local medication experience of a patient is improved while the administration convenience is ensured. Besides, through reasonable selection of auxiliary materials, the cream formed through conversion can provide proper adhesion, and the retention time of the medicine at the action part can be prolonged.

This invention relates to a topical agent for preventing and treating poplar canker and its application method. The topical agent, by weight percentage, comprises the following ingredients: 0.1-0.2% pyraclostrobin; 1-3% wetting and dispersing agent; 0.2%-0.8% thickener; 2-4% antifreeze agent; 0.01%-0.3% micronutrient fertilizer; 0.1%-0.3% defoamer; and the balance being deionized water. Before application, first use a scraper to clean the ulcerated areas on the poplar branches and trunks, thoroughly scraping away the rotten tissue, extending 2-3 cm beyond the diseased area on both the upper and lower surfaces. Then, evenly and promptly apply the topical agent to the treated wound surface, cover it with breathable non-woven fabric, and then apply another layer of topical agent over the non-woven fabric, ensuring close adhesion to the branches and trunk. The topical agent of this invention is simple to use, highly effective, and can effectively control canker, reduce the impact on poplar growth, and achieve efficient prevention and treatment of poplar canker.

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

The present invention provides compositions and methods for orally and / or topically treating skin diseases and conditions, such as acne, atopic dermatitis, psoriasis, facial redness, folliculitis, dry skin, itchy skin, hyperpigmentation, aging, wrinkles, etc., by administering to a subject in need thereof a pharmaceutical composition or dietary supplement comprising an in vitro grown grape cell line culture. Additionally, the present invention provides methods and compositions for treating skin conditions and diseases, such as acne, atopic dermatitis, psoriasis, facial redness, folliculitis, dry skin, itchy skin, aging, wrinkles, etc., by topically administering to a subject in need thereof a pharmaceutical composition or cosmetic composition comprising an in vitro grown grape cell line culture.

A method for treating an allergy condition of an animal includes detecting that the animal has one or more allergy condition, where the one or more allergy condition comprises one or more plant-based allergen, one or more mold or fungus-based allergen, one or more mite or insect-based allergen, or a combination thereof. The method includes determining a first quantity of a topical application medium and a first quantity of the one or more allergens based at least in part on one or more attributes of the animal. The method includes providing a first topical application compound, the first topical application compound comprising the first quantity of the one or more allergens and the first quantity of the topical application medium. The method includes applying the first topical application compound to the animal to treat the allergy condition.

The invention is implemented into the category of transdermal topical agents for use in regulating the dilation of blood vessels. The IP-6, Inositol, and colloidal oatmeal Nerve Relaxing Transdermal Topical Cream, Gel, or Ointment for Raynaud's Syndrome is the first topical cream containing any or all of the following: IP-6, inositol, and colloidal oatmeal, with IP-6 as the carrier agent. The present invention will allow for the decrease in the time to full clinical effect, eliminate having to wear a patch of paper over the application site, and eliminate the problem of skin irritation due to the IP-6 delivering the colloidal oatmeal to the application area to provide extra soothing and moisturizing properties. The present invention is specifically and uniquely designed for ease of use and quick action of full clinical effect with the relaxation of nerve endings that lead to dilation of extremely constricted blood vessels in mind.

This invention discloses a traditional Chinese medicine composition for the prevention and treatment of throat and oral diseases, and its preparation method. The composition comprises poultry egg yolk oil, honey, platycodon root, dandelion, licorice, monk fruit, menthol, and maltose in specific weight proportions. Its preparation includes steps such as frying poultry egg yolk oil, preparing water extracts of platycodon root and dandelion, and mixing with maltose to form a final product. The composition of this invention uses only food-grade medicinal materials, ensuring safety and reliability. When formulated into topical dosage forms such as lozenges, it provides long-lasting effects on the affected area, offering multiple benefits including analgesia, anti-inflammation, mucosal repair, and cough suppression. It effectively solves the problems of significant side effects and limited duration of local application in existing oral medications. This product has a pleasant taste and high patient compliance, making it suitable for the prevention and treatment of throat and oral diseases such as pharyngitis, tonsillitis, oral ulcers, gingivitis, and sore throat.

A new means of intradermal delivery of a useful component is provided. Disclosed are an external-use skin preparation composition comprising fine needlelike taurine crystals including a useful component in the crystals, and a method for producing a fine needlelike taurine crystal including a useful component in the crystal, the method comprising a step of growing a crystal in an environment in which an aqueous solution (A) containing taurine dissolved is mixed with or held in contact with a liquid substance (B) having low solubility of taurine, wherein the useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), whereby the useful component is included in the crystal along with the growth of the crystal.

In one aspect, the disclosure relates to clearing compounds capable of rendering at least one tissue transparent for a period of time, compositions comprising the same, pendant molecules bonded to the compounds capable of covalently or non-covalently binding to tissue such as collagen mimetic peptide, and macromolecules derivatized with the same. In another aspect, the compositions can be useful in clinic for visualizing internal anatomical structures and / or for clearing opacities of the eye. In one aspect, the compositions are topical, e.g., eye drops, lotions, or creams, or are injectable. In some aspects, an injection is performed directly into opaque tissue such as neural tissue, connective tissue, internal organs, ocular tissue, or the like. In other aspects, the clearing compound is injected adjacent to the target structure. The clearing compounds can be colorless across the entire visible spectrum, are non-toxic, and are excreted by the subject after visualization of tissue structures.

Embodiments disclosed provide pharmaceutical formulations for tyrosinase inhibitors, as well as methods for dermatological treatment of hyperpigmentation disorders. The pharmaceutical formulations comprise tyrosinase inhibitors, each containing a structural core of 8-hydroxyquinoline, and are applied in a suitable carrier as topical treatments for hyperpigmentation. In some embodiments at least one additional dermatologically active compound is present in the pharmaceutical formulation.

Provided is a topical composition for treating a skin condition such as acne vulgaris in a subject in need thereof. In particular, the topical composition comprises 2% salicylic acid as an active agent; 15% dimethyl sulfoxide operating as a tissue penetrating solvent; 85% dipropylene glycol as a tissue penetrating diluent; oleic acid as a tissue penetrating agent; and a stabilizer comprising 1% ascorbic acid for maintaining the composition, which also functions to maintain chemical stability and resistance to degradation.

To provide an oil-in-water type skin external preparation that exhibits high transparency after application and possesses good feel in use and stability by combined use of specific components.SOLUTION: An oil-in-water type skin external preparation contains the following (A) to (C): (A) cellulose nanofiber, (B) sucrose fatty acid ester and (C) triethoxycaprylylsilane-treated powder.SELECTED DRAWING: None

1. Name of the product in this design: Electric fiber powder sprayer. 2. Application of this design: This design is intended for use as a powder sprayer for cosmetics, beauty treatments, and medical applications, used to spray fibrous topical agents, beauty agents, cosmetics, etc., onto the skin. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

It is known that pollutants such as pollen and PM2 5 to which we are exposed in daily life, and blue light emitted by displays of electronic devices such as personal computers and smartphones damage the skin. Pollutants and blue light generate reactive oxygen species (ROS) in cells, cause lipid oxidation, protein glycation, and the like, and cause the occurrence of wrinkles and sagging, a decrease in the transparency of the skin, and the like. In such a background, research on components that suppress ROS production has been advanced, and external preparations have been developed, but the effects thereof are not necessarily satisfactory.SOLUTION: To provide a new external preparation composition for skin or hair care suppressing ROS production and improving skin conditions by formulating an extract of a fruit of Terminalia chebula.SELECTED DRAWING: Figure 1

There is provided an applicator head (10) for administration of a topical formulation, comprising a dosing aid for application of a predefined dose of the topical formulation. The applicator head (10) comprises an applicator surface (20) adapted to apply the topical formulation to a user's skin. The applicator surface (20) comprises an outlet opening (40). The dosing aid comprises a dose marking, or dose markings (60, 60′, 60″, 62′, 62″) on the applicator surface (20), and wherein the dose marking (60, 60′, 60″, 62′, 62″) circumscribes an inner dosing compartment (64) that serves to measure the predefined dose of the topical formulation, and wherein the outlet opening (40) is disposed inside the inner dosing compartment.

To find out a new function of Myonectin and to provide a suitable use thereof.SOLUTION: The myonectin production promoter is contained in a composition for inhibiting IL-1 α expression. The composition is preferably in the form of an external preparation for skin or a food or drink.SELECTED DRAWING: Figure 1

This inexpensive and simple protective device effectively prevents people with skin conditions on their arms from unconsciously touching or scratching the affected area while sleeping, and prevents topical medications applied to the affected area from being rubbed off by clothing, thereby contributing to the improvement of their condition. [Solution] The protective device 10 comprises an end-side ring member 20 for attachment to the tip of the limbs or fingers and toes, a base-side ring member 30 for attachment to the base of the limbs or fingers and toes, and suspension members 40, 40... suspended between the end-side ring member and the base-side ring member. Therefore, the protective device 10 ensures a gap (space) between the suspension members 40, 40... and the surface of the skin on the arm, thereby effectively preventing the user (wearer) from unconsciously touching or scratching the affected area of ​​the arm affected by a skin disease while sleeping.

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

This invention relates to the field of traditional Chinese medicine preparations, and discloses a topical preparation of black alum for treating malaria and rapidly regulating anemia. It is composed of black alum, cinnabar, artemisia annua extract, dichroa febrifuga extract, angelica sinensis extract, astragalus membranaceus extract, and pharmaceutical excipients. Based on black alum and cinnabar, this invention incorporates artemisia annua extract and dichroa febrifuga extract. Black alum exerts its insecticidal effect by disrupting the cell membrane structure of Plasmodium; cinnabar inhibits nucleic acid synthesis in Plasmodium; artemisinin interferes with mitochondrial function in Plasmodium; and dichroa febrifuga alkaloids inhibit protein synthesis in Plasmodium. The preparation is made into a nasal powder, administered through nasal inhalation. It is directly absorbed into the bloodstream through the rich capillaries of the nasal mucosa, rapidly replenishing the body's iron and promoting hemoglobin synthesis. The added angelica sinensis and astragalus membranaceus extracts have blood-tonifying and qi-boosting effects, enhancing the body's hematopoietic function, improving microcirculation, and accelerating the improvement of anemia symptoms.

The present invention provides peroxidase-based pharmaceutical, prophylactic, and cosmetic compositions. The compositions are preferably formulated for topical use. More specifically, the present invention relates to peroxidase-based compositions that further comprise a compound that enhances and / or stabilizes the activity of antimicrobial peroxidase. The present invention also provides methods and uses that include the compositions of the present invention.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The present invention relates to an anti-aging composition, which is achieved by a topical composition containing a specific amino acid and a specific dicarboxylic acid or ester that synergistically enhances the gene expression of collagen 1, an indicator of anti-aging efficacy in the skin.